Head and Neck Cancer Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial
In this multicenter randomized trial, the clinical benefit and safety of definitive RT with reduced versus standard elective dose were compared.
The phase 3 KEYNOTE‑689 trial evaluated the addition of pembrolizumab to standard therapy (surgery followed by radiation or radiation plus chemotherapy) in patients with locally advanced, previously untreated stage 3–4 HNSCC whose tumors expressed PD‑L1. At 36 months, event‑free survival was 60 % in the pembrolizumab arm versus 46 % in the control arm, representing a 27 % relative reduction in recurrence risk.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability